New lupus drug trial aims to tame the immune system
NCT ID NCT07538154
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine, SCTC21C, in 159 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The goal is to see if the drug is safe and can reduce lupus symptoms. Participants must be on stable standard treatments and will receive the study drug in addition to their usual care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.